Sustained angiogenesis stands as a hallmark of cancer. The intricate vascular tumor microenvironment fuels cancer progression and metastasis, fosters therapy resistance, and facilitates immune evasion. Therapeutic strategies targeting tumor vasculature have emerged as transformative for cancer treatment, encompassing anti-angiogenesis, vessel normalization, and endothelial reprogramming. Growing evidence suggests the dynamic regulation of tumor angiogenesis by infiltrating myeloid cells, such as macrophages, myeloid-derived suppressor cells (MDSCs), and neutrophils. Understanding these regulatory mechanisms is pivotal in paving the way for successful vasculature-targeted cancer treatments. Therapeutic interventions aimed to disrupt myeloid cell-mediated tumor angiogenesis may reshape tumor microenvironment and overcome tumor resistance to radio/chemotherapy and immunotherapy.
Keyphrases
- endothelial cells
- papillary thyroid
- vascular endothelial growth factor
- induced apoptosis
- acute myeloid leukemia
- dendritic cells
- bone marrow
- cell therapy
- single cell
- squamous cell
- stem cells
- cell cycle arrest
- physical activity
- cancer therapy
- squamous cell carcinoma
- immune response
- oxidative stress
- endoplasmic reticulum stress